Allergy Research
·Jan 27, 2023
Forrest Family Invests In Australian Peanut Allergy Therapy Development
Aravax is a Melbourne-based biotechnology company developing the first precisely targeted immunotherapeutic for peanut allergy, PVX108. An investment of US$20m from Australian investors, Brandon Capital and Tenmile will support Phase 2 trials. PVX108 does not contain peanut protein but is…